地塞米松联合恩替卡韦治疗早期乙型肝炎相关肝衰竭患者的疗效及安全性分析 : = Efficacy Analysis of Dexamethasone Combined with Entecavir in the Treatment of Early Hepatitis B-related Liver Failure
目的分析地塞米松联合恩替卡韦治疗早期乙型肝炎相关肝衰竭患者的疗效及安全性。方法选取2017年5月～2019年5月我院早期乙型肝炎相关肝衰竭患者107例,按治疗方案不同分为观察组(n=54)、参照组(n=53)。参照组在常规内科综合治疗基础上采用恩替卡韦治疗,观察组在参照组基础上采用地塞米松治疗。比较两组总有效率、治疗前后血清总胆红素(TBil)、丙氨酸氨基转移酶(ALT)、总胆固醇(TC)、凝血酶原活动度(PTA)水平、不良反应发生率。结果观察组总有效率为88.89%(48/54),高于参照组60.38%(32/53)(P<0.05);治疗后观察组TBil、ALT水平低于参照组,TC、PTA水平高于参照组(P<0.05);两组不良反应发生率比较无显著差异(P>0.05)。结论地塞米松联合恩替卡韦治疗早期乙型肝炎相关肝衰竭患者临床疗效显著,可有效改善患者临床症状及肝功能,且具有安全性。.
Objective To analyze the efficacy of dexamethasone combined with entecavir in the treatment of early hepatitis B-related liver failure. Methods 107 patients with early hepatitis B-related liver failure in our hospital from May 2017 to May 2019 were selected. According to the treatment plan,the experimental group(n=54) and the reference group(n=53) were divided. The reference group was treated with entecavir on the basis of conventional medical comprehensive treatment,and the test group was treated with dexamethasone on the basis of the reference group. The total effective rate,serum total bilirubin(TBil),alanine aminotransferase(ALT),total cholesterol(TC),prothrombin activity(PTA) levels,and incidence of adverse reactions were compared before and after treatment. Results The total effective rate of the experimental group was 88.89%(48/54),which was higher than that of the reference group(60.38%(32/53)(P<0.05). After treatment,the TBil and ALT levels in the experimental group were lower than the reference group,and the TC and PTA levels were high. In the reference group(P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion The clinical efficacy of dexamethasone combined with entecavir in the treatment of patients with early hepatitis B-related liver failure is significant,which can effectively improve the clinical symptoms and liver function of patients safely..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019-12-31 2019 |
|---|---|
| Erschienen: |
2019-12-31 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2019 |
|---|---|
| Enthalten in: |
Kou an wei sheng kong zhi - (2019), 06 vom: 31. Dez., Seite 42-45 Original Letters: Enthalten in 口岸卫生控制 (DE-600)2991407-3 (DE-600)2991407-3 天津市 |
| Reihe: |
China Academic Journals (CAJ), E, 医药卫生科技 = Medicine & Public Health |
|---|
| Sprache: |
Chinesisch |
|---|
| Weiterer Titel: |
Efficacy Analysis of Dexamethasone Combined with Entecavir in the Treatment of Early Hepatitis B-related Liver Failure |
|---|
| Beteiligte Personen: |
郝娟 [VerfasserIn] |
|---|
| Links: |
oversea.cnki.net [lizenzpflichtig] |
|---|
| Anmerkungen: |
Author info:Hao Juan;People's Hospital of Qixian |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
CAJ64596770X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CAJ64596770X | ||
| 003 | DE-627 | ||
| 005 | 20230121123825.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230104s2019 cc |||||o 00| ||chi c | ||
| 035 | |a (DE-627)CAJ64596770X | ||
| 035 | |a (SBB-XA)CAJ_KAWS201906014 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 044 | |c XB-CN | ||
| 084 | |a ASIEN |q DE-1a |2 fid | ||
| 084 | |a R512.62 |2 clc | ||
| 084 | |a R575.3 |2 clc | ||
| 100 | 0 | |a 郝娟 |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 地塞米松联合恩替卡韦治疗早期乙型肝炎相关肝衰竭患者的疗效及安全性分析 |b = Efficacy Analysis of Dexamethasone Combined with Entecavir in the Treatment of Early Hepatitis B-related Liver Failure |
| 246 | 3 | 1 | |a Efficacy Analysis of Dexamethasone Combined with Entecavir in the Treatment of Early Hepatitis B-related Liver Failure |
| 264 | 1 | |c 2019-12-31 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a China Academic Journals (CAJ) |a E |a 医药卫生科技 = Medicine & Public Health | |
| 500 | |a Author info:Hao Juan;People's Hospital of Qixian | ||
| 520 | |a 目的分析地塞米松联合恩替卡韦治疗早期乙型肝炎相关肝衰竭患者的疗效及安全性。方法选取2017年5月～2019年5月我院早期乙型肝炎相关肝衰竭患者107例,按治疗方案不同分为观察组(n=54)、参照组(n=53)。参照组在常规内科综合治疗基础上采用恩替卡韦治疗,观察组在参照组基础上采用地塞米松治疗。比较两组总有效率、治疗前后血清总胆红素(TBil)、丙氨酸氨基转移酶(ALT)、总胆固醇(TC)、凝血酶原活动度(PTA)水平、不良反应发生率。结果观察组总有效率为88.89%(48/54),高于参照组60.38%(32/53)(P<0.05);治疗后观察组TBil、ALT水平低于参照组,TC、PTA水平高于参照组(P<0.05);两组不良反应发生率比较无显著差异(P>0.05)。结论地塞米松联合恩替卡韦治疗早期乙型肝炎相关肝衰竭患者临床疗效显著,可有效改善患者临床症状及肝功能,且具有安全性。 | ||
| 520 | |a Objective To analyze the efficacy of dexamethasone combined with entecavir in the treatment of early hepatitis B-related liver failure. Methods 107 patients with early hepatitis B-related liver failure in our hospital from May 2017 to May 2019 were selected. According to the treatment plan,the experimental group(n=54) and the reference group(n=53) were divided. The reference group was treated with entecavir on the basis of conventional medical comprehensive treatment,and the test group was treated with dexamethasone on the basis of the reference group. The total effective rate,serum total bilirubin(TBil),alanine aminotransferase(ALT),total cholesterol(TC),prothrombin activity(PTA) levels,and incidence of adverse reactions were compared before and after treatment. Results The total effective rate of the experimental group was 88.89%(48/54),which was higher than that of the reference group(60.38%(32/53)(P<0.05). After treatment,the TBil and ALT levels in the experimental group were lower than the reference group,and the TC and PTA levels were high. In the reference group(P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion The clinical efficacy of dexamethasone combined with entecavir in the treatment of patients with early hepatitis B-related liver failure is significant,which can effectively improve the clinical symptoms and liver function of patients safely. | ||
| 610 | 2 | 4 | |a 河南省杞县人民医院 |
| 650 | 4 | |a 传染病 | |
| 650 | 4 | |a 内科学 | |
| 650 | 4 | |a 医药、卫生 | |
| 650 | 4 | |a 消化系及腹部疾病 | |
| 650 | 4 | |a Infectious Disease | |
| 650 | 4 | |a Digestive System Disease | |
| 650 | 4 | |a Emergency Medicine | |
| 650 | 4 | |a 医药卫生科技 | |
| 650 | 4 | |a Medicine & Public Health | |
| 650 | 4 | |a 地塞米松 | |
| 650 | 4 | |a 恩替卡韦 | |
| 650 | 4 | |a 早期乙型肝炎相关肝衰竭 | |
| 650 | 4 | |a Dexamethasone | |
| 650 | 4 | |a Entecavir | |
| 650 | 4 | |a Early Hepatitis B-related Liver Failure | |
| 773 | 0 | 8 | |6 880-01 |i Enthalten in |t Kou an wei sheng kong zhi |d Tian jin shi, 1996 |g (2019), 06 vom: 31. Dez., Seite 42-45 |h Online-Ressource |w (DE-627)CAJ172591295 |w (DE-600)2991407-3 |7 nnns |
| 773 | 1 | 8 | |g year:2019 |g number:06 |g day:31 |g month:12 |g pages:42-45 |
| 856 | 4 | 0 | |u http://erf.sbb.spk-berlin.de/han/caj/oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=KAWS201906014 |x Verlag |y CrossAsia Link |z Deutschlandweit zugänglich |
| 856 | 4 | 0 | |u https://oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=KAWS201906014 |x Verlag |z lizenzpflichtig |
| 880 | 0 | 8 | |6 773-01/Hans |i Enthalten in |t 口岸卫生控制 |d 天津市 |h Online-Ressource |w (DE-627)CAJ172591295 |w (DE-600)2991407-3 |7 nnns |
| 912 | |a ZDB-1-CAJ | ||
| 912 | |a GBV_NL_CAJ | ||
| 912 | |a FID-ASIEN | ||
| 912 | |a SSG-OLC-OA3.1 | ||
| 912 | |a SSG-OLC-CAJ | ||
| 936 | u | w | |j 2019 |e 06 |b 31 |c 12 |h 42-45 |
| 951 | |a AR | ||
| 952 | |j 2019 |e 06 |b 31 |c 12 |h 42-45 | ||
| 980 | |2 11 |1 01 |x 0001 |b 665472439 |c 00 |f 5:FIDXASIA |d --%%-- |e --%%-- |j --%%-- |y k |z 04-01-23 | ||
| 981 | |2 11 |1 01 |x 0001 |r http://erf.sbb.spk-berlin.de/han/caj/oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=KAWS201906014 | ||